(Oxford, UK, 3 December, 2015) Immunocore Limited, a world-leading biotechnology company developing novel T cell receptor (TCR) based biological drugs to treat cancer, viral infections and autoimmune disease, was awarded Biotech of the Year at last night’s SCRIP Awards 2015.
2015 has been a transformational year for Immunocore, which has seen the company advancing the clinical development of its lead candidate, IMCgp100, in advanced melanoma, advancing its partnerships with international pharmaceutical partners to develop novel immuno-oncology assets, entering into clinical combination trial collaborations, strengthening its executive team and Board, and future-proofing its balance sheet with a $320 million Series A fundraising giving the company significant financial flexibility.
The SCRIP Awards, now in its 11th year, is among the most prestigious in the calendar for the life sciences industry. The Biotech of the Year Award acknowledges excellence in the large and small pharmaceutical and biotechnology companies.
Eliot Forster, Chief Executive Officer of Immunocore, commented: “We are honoured to have received this award. Immunocore has had a good year, with strong advances in our clinical and corporate development and an investment round giving us the financial strength to focus on securing the best clinical outcome for our lead candidate, IMCgp100 and our internal and partner programmes. To receive acknowledgement from our peers of the continued excellence, all thanks to the hard work of our Board, investors and staff, is extremely gratifying.”
Please click on the link below to download the full Press Release: